CMC, Dossier Compilation & Regulatory Support​

**Advancing regulated products across global markets requires a CRDO with integrated CMC depth, QbD discipline, BE/PK expertise, and broad-spectrum regulatory intelligence. Healios Labs embeds TPP/QTPP-to-CQA mapping, design-space justification, and risk-based development logic into every complex generic, 505(b)(2), biosimilar, and NME program. Our framework integrates ICH Q8–Q12, ICH M4Q structuring, PBPK–BE correlations, impurity-qualification methodology, stability trending algorithms, and phase-appropriate validation to ensure alignment across eCTD Modules 2, 3, and 5. Using Dossier Architecture Thinking, structured guideline interpretation, global regulatory-landscape analytics, and lifecycle-ready documentation within Pinnacle-class regulatory platforms, Healios anticipates FDA, EMA, PMDA, MHRA, and TGA expectations to reduce post-submission variability. This integrated, proactive approach delivers tangible business impact by reducing time-to-approval, minimising regulatory setbacks, and lowering overall development costs, enabling our clients to achieve faster market entry and sustained competitive advantage.**

**Healios provides end-to-end regulatory support spanning development strategy, CMC dossier authoring, clinical/nonclinical summarisation, labeling, submissions, and lifecycle management. Unlike traditional regulatory vendors who often deliver compartmentalized or templated services, Healios combines advanced scientific rationale, data-driven dossier architecture, and global regulatory strategy within a unified, agile model. Our teams prepare scientific-justification packages, literature-based rationales, analytical-method lifecycle files, nitrosamine and E&L assessments, specification-setting logic, and statistical justification frameworks. We conduct query-readiness conditioning, RFI simulations, deficiency-response mapping, and Pre-IND/Scientific-Advice briefing preparation with structured correspondence tools. Our validated publishing workflows utilise Pinnacle-style XML/eCTD compilers, automated granularity mapping, hyperlink governance engines, metadata validation, and compliant transmissions through FDA ESG, EMA IRIS, and other national gateways. As a result, Healios clients benefit from more resilient submissions, faster regulatory interactions, and a reduced risk of delays or rework compared to industry-standard approaches. This integrated regulatory model strengthens dossier defensibility, accelerates multi-market approvals, and minimises sponsor burden.**